SwePub
Sök i LIBRIS databas

  Utökad sökning

(WFRF:(Ganguly Siddhartha)) mspu:(article)
 

Sökning: (WFRF:(Ganguly Siddhartha)) mspu:(article) > (2014) > Early Failure of Fr...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005240naa a2200817 4500
001oai:DiVA.org:uu-236521
003SwePub
008141119s2014 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:129910946
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-2365212 URI
0247 a https://doi.org/10.1016/j.bbmt.2014.06.0362 DOI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1299109462 URI
040 a (SwePub)uud (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Hamadani, Mehdi4 aut
2451 0a Early Failure of Frontline Rituximab-Containing Chemo-immunotherapy in Diffuse Large B Cell Lymphoma Does Not Predict Futility of Autologous Hematopoietic Cell Transplantation
264 1b Elsevier BV,c 2014
338 a print2 rdacarrier
520 a The poor prognosis for patients with diffuse large B cell lymphoma (DLBCL) who relapse within 1 year of initial diagnosis after first-line rituximab-based chemo-immunotherapy has created controversy about the role of autologous transplantation (HCT) in this setting. We compared autologous HCT outcomes for chemosensitive DLBCL patients between 2000 and 2011 in 2 cohorts based on time to relapse from diagnosis. The early rituximab failure (ERF) cohort consisted of patients with primary refractory disease or those with first relapse within 1 year of initial diagnosis. The ERF cohort was compared with those relapsing >1 year after initial diagnosis (late rituximab failure [LRF] cohort). ERF and LRF cohorts included 300 and 216 patients, respectively. Nonrelapse mortality (NRM), progression/relapse, progression-free survival (PFS), and overall survival (OS) of ERF versus LRF cohorts at 3 years were 9% (95% confidence interval [CI], 6% to 13%) versus 9% (95% CI, 5% to 13%), 47% (95% CI, 41% to 52%) versus 39% (95% CI, 33% to 46%), 44% (95% CI, 38% to 50%) versus 52% (95% CI, 45% to 59%), and 50% (95% CI, 44% to 56%) versus 67% (95% CI, 60% to 74%), respectively. On multivariate analysis, ERF was not associated with higher NRM (relative risk [RR], 1.31; P = .34). The ERF cohort had a higher risk of treatment failure (progression/relapse or death) (RR, 2.08; P < .001) and overall mortality (RR, 3.75; P < .001) within the first 9 months after autologous HCT. Beyond this period, PFS and OS were not significantly different between the ERF and LRF cohorts. Autologous HCT provides durable disease control to a sizeable subset of DLBCL despite ERF (3-year PFS, 44%) and remains the standard-of-care in chemosensitive DLBCL regardless of the timing of disease relapse.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaperx Immunologi inom det medicinska området0 (SwePub)301102 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Basic Medicinex Immunology in the medical area0 (SwePub)301102 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Hematologi0 (SwePub)302022 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Hematology0 (SwePub)302022 hsv//eng
653 a Autologous transplantation
653 a Rituximab
653 a Early failure
653 a High-dose therapy
653 a Diffuse large B cell lymphoma
653 a Aggressive lymphoma
653 a Non-Hodgkin lymphoma
7001 a Hari, Parameswaran N.4 aut
7001 a Zhang, Ying4 aut
7001 a Carreras, Jeanette4 aut
7001 a Akpek, Goerguen4 aut
7001 a Aljurf, Mahmoud D.4 aut
7001 a Ayala, Ernesto4 aut
7001 a Bachanova, Veronika4 aut
7001 a Chen, Andy I.4 aut
7001 a Chen, Yi-Bin4 aut
7001 a Costa, Luciano J.4 aut
7001 a Fenske, Timothy S.4 aut
7001 a Freytes, Cesar O.4 aut
7001 a Ganguly, Siddhartha4 aut
7001 a Hertzberg, Mark S.4 aut
7001 a Holmberg, Leona A.4 aut
7001 a Inwards, David J.4 aut
7001 a Kamble, Rammurti T.4 aut
7001 a Kanfer, Edward J.4 aut
7001 a Lazarus, Hillard M.4 aut
7001 a Marks, David I.4 aut
7001 a Nishihori, Taiga4 aut
7001 a Olsson, Richardu Karolinska Institutet,Uppsala universitet,Centrum för klinisk forskning i Sörmland (CKFD)4 aut0 (Swepub:uu)riols677
7001 a Reddy, Nishitha M.4 aut
7001 a Rizzieri, David A.4 aut
7001 a Savani, Bipin N.4 aut
7001 a Solh, Melhem4 aut
7001 a Vose, Julie M.4 aut
7001 a Wirk, Baldeep4 aut
7001 a Maloney, David G.4 aut
7001 a Smith, Sonali M.4 aut
7001 a Montoto, Silvia4 aut
7001 a Saber, Wael4 aut
7102 a Uppsala universitetb Centrum för klinisk forskning i Sörmland (CKFD)4 org
7730 t Biology of blood and marrow transplantationd : Elsevier BVg 20:11, s. 1729-1736q 20:11<1729-1736x 1083-8791x 1523-6536
8564 u http://www.bbmt.org/article/S1083879114004030/pdf
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-236521
8564 8u https://doi.org/10.1016/j.bbmt.2014.06.036
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:129910946

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy